Premium
Pediatric P‐ANCA vasculitis following COVID‐19
Author(s) -
Fireizen Yaron,
Shahriary Cyrus,
Imperial Maria E.,
Randhawa Inderpal,
Nianiaris Nastasia,
Ovunc Bugsu
Publication year - 2021
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.25612
Subject(s) - medicine , vasculitis , plasmapheresis , anti neutrophil cytoplasmic antibody , systemic vasculitis , pulmonary hemorrhage , immunology , population , pneumonia , pathology , antibody , lung , disease , environmental health
Background Perinuclear anti‐neutrophil cytoplasmic antibodies (P‐ANCA) are associated with a multisystem vasculitis affecting small blood vessels in the body. A handful of adult patients who developed vasculitis post‐COVID‐19 have been reported. Although SARS‐CoV‐2 has been shown to drive an exaggerated immune response in the pediatric population, such as in Multisystem Inflammatory Syndrome in Children (MIS‐C), only one case of vasculitis following COVID‐19 has been reported previously in children. Case presentation Seventeen‐year‐old male with a past medical history of COVID‐19 pneumonia two months prior presented with acute kidney injury and diffuse alveolar hemorrhage. Rheumatologic workup revealed P‐ANCA and Myeloperoxidase (MPO) positivity. Kidney biopsy showed necrotizing glomerulonephritis with limited immune complex deposition. Subsequently, he was treated with steroids and plasmapheresis, and ultimately started on cyclophosphamide. Conclusions To our knowledge, this report presents the second reported pediatric case of P‐ANCA/MPO vasculitis following COVID‐19.